We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Carlyle Group (CG) to Retreat From China Real Estate Market
Read MoreHide Full Article
The Carlyle Group L.P. (CG - Free Report) plans to phase out its Chinese real estate team by the end of this year, per a report by Bloomberg. The company, which has been trying to revamp its Asian Unit, has decided to shift its focus from the Chinese real estate market due to decline in investors’ interest for country-specific funds.
Notably, the company made key changes in its executive leadership team in 2017, which got into effect from Jan 1, 2018. Since then, the newly constituted team has been making moves to reconsider and improve the company’s strategy.
Initially, this team was focused on investing in China’s real estate market. However, Carlyle noted that there was significant demand for separately-managed accounts for investing in Chinese real estate, instead of its China-specific real estate investments. Therefore, the team decided to retreat from investing in the country’s real estate market.
On this, Brooke Coburn, deputy chief investment officer of Carlyle’s real assets segment, stated, “We discovered a nuance when it comes to investors and traditional funds in the Chinese market. Investors want to be more prescriptive on terms including the timing of the exit or pursue either smaller transactions or deals that require shared control.”
Subsequent to the team phase out, the company will invest in Asia’s real estate market through Carlyle Asia Partners V LP — its primary fund for investing in this market.
Per the fresh executive team, the company has created an integrated platform which focuses on one-team approach for its Asian business. Further, the company plans to focus on ensuring optimal allocation of strategic resources. This, in turn, will likely boost the company’s profitability over the long run.
The company’s shares have gained 1.1% over the past three months, as against the industry’s decline of 7.9%. The stock currently carries a Zacks Rank #3 (Hold).
Lazard’s earnings estimates for 2018 have been revised 3.2% upward over the past 60 days. Its shares have rallied 11.1% in a year’s time.
Over the last 60 days, the Zacks Consensus Estimate for Prospect Capital’s current-year earnings moved 13.3% north. Its share price has gained 7.2% in the past year.
Over the last 60 days, Ameriprise Financial’s 2018 earnings estimate inched up 1.3%. Over the past year, its share price has appreciated 4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Carlyle Group (CG) to Retreat From China Real Estate Market
The Carlyle Group L.P. (CG - Free Report) plans to phase out its Chinese real estate team by the end of this year, per a report by Bloomberg. The company, which has been trying to revamp its Asian Unit, has decided to shift its focus from the Chinese real estate market due to decline in investors’ interest for country-specific funds.
Notably, the company made key changes in its executive leadership team in 2017, which got into effect from Jan 1, 2018. Since then, the newly constituted team has been making moves to reconsider and improve the company’s strategy.
Initially, this team was focused on investing in China’s real estate market. However, Carlyle noted that there was significant demand for separately-managed accounts for investing in Chinese real estate, instead of its China-specific real estate investments. Therefore, the team decided to retreat from investing in the country’s real estate market.
On this, Brooke Coburn, deputy chief investment officer of Carlyle’s real assets segment, stated, “We discovered a nuance when it comes to investors and traditional funds in the Chinese market. Investors want to be more prescriptive on terms including the timing of the exit or pursue either smaller transactions or deals that require shared control.”
Subsequent to the team phase out, the company will invest in Asia’s real estate market through Carlyle Asia Partners V LP — its primary fund for investing in this market.
Per the fresh executive team, the company has created an integrated platform which focuses on one-team approach for its Asian business. Further, the company plans to focus on ensuring optimal allocation of strategic resources. This, in turn, will likely boost the company’s profitability over the long run.
The company’s shares have gained 1.1% over the past three months, as against the industry’s decline of 7.9%. The stock currently carries a Zacks Rank #3 (Hold).
Key Picks
A few better-ranked stocks in the same space are Lazard Ltd (LAZ - Free Report) , Prospect Capital Corporation (PSEC - Free Report) and Ameriprise Financial, Inc. (AMP - Free Report) . All three stocks carry a Zacks Rank of 2 (Buy). You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lazard’s earnings estimates for 2018 have been revised 3.2% upward over the past 60 days. Its shares have rallied 11.1% in a year’s time.
Over the last 60 days, the Zacks Consensus Estimate for Prospect Capital’s current-year earnings moved 13.3% north. Its share price has gained 7.2% in the past year.
Over the last 60 days, Ameriprise Financial’s 2018 earnings estimate inched up 1.3%. Over the past year, its share price has appreciated 4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>